Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 11:11 AM
Ignite Modification Date:
2025-12-26 @ 11:11 AM
NCT ID:
NCT06006728
Eligibility Criteria:
Inclusion Criteria:
* 18 years or older
* histological or cytological confirmation of pancreatic ductal adenocarcinoma
* measurable lesion(s)
* progression after gemcitabine-based treatment administered in a neoadjuvant, adjuvant protocol (only if remote metastases developed within 6 months of the end of adjuvant treatment), locally advanced, or metastatic phase. They may have already received irinotecan and/or fluorouracil.
* Performance Status (PS) 0 or 1
* Oral consent
* Health insurance
Exclusion Criteria:
* symptomatic brain metastases (cerebral edema, corticosteroids, progressive disease)
* thromboembolic events within six months of inclusion;
* Class III or IV congestive heart failure, ventricular arrhythmia, uncontrolled hypertension.
* Patient under legal protection
* Hypersensitivity to irinotecan
* Breast feeding
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06006728
Study Brief:
Protocol Section:
NCT06006728